Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • João Pedro Melo Marques Pinho Ferreira

    Autor

  • Francisco Aguiar Vasques Novoa Faria

    Autor

  • Marta Borges Canha

    Autor

  • Davide Maurício Costa Carvalho

    Autor

  • João Sérgio De Lima Soares Neves

    Autor

Participantes de fora da FMUP

  • Sharma, A
  • Angelico Goncalves, A
  • Leite, AR
  • Packer, M
  • Zannad, F
  • Leite Moreira, A.

Unidades de investigação

Abstract

Aim Glucagon-like peptide-1 receptor agonists (GLP1-RA) improve cardiovascular outcomes in patients with type 2 diabetes (T2D). However, some studies suggest that their effects in patients with heart failure (HF) may be attenuated. We aimed to explore the effects of the GLP1-RA albiglutide on HF outcomes in patients with and without HF history enrolled in the Harmony Outcomes trial. Methods and results Harmony Outcomes enrolled patients with T2D and cardiovascular disease randomized to either albiglutide or placebo over a median follow-up of 1.6 years. A total of 9462 patients were included, of whom 1922 (20%) had HF history. Patients with HF had more cardiovascular comorbidities, poorer renal function, and had a three to four-fold higher risk of HF events compared to patients without HF. Compared to placebo, the effect of albiglutide on the composite of cardiovascular death or HF hospitalization was more pronounced among patients without HF (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56-0.95) than in patients with HF (HR 1.06, 95% CI 0.79-1.43) (interaction p = 0.062). A similar pattern was observed for HF hospitalizations (interaction p = 0.025). The effect of albiglutide on cardiovascular death, sudden death or 'pump failure' death, and all-cause mortality was also attenuated among patients with HF history, but without significant interaction (p > 0.1). The benefit of albiglutide to reduce atherosclerotic events was consistent regardless of HF history. Conclusions In patients with T2D and cardiovascular disease, albiglutide appeared to have no effect in reducing HF-related events among patients with HF history. These findings, placed in the context of other trials, suggest that GLP1-RA may not improve HF outcomes in patients with HF.

© 2022 European Society of Cardiology.

Dados da publicação

ISSN/ISSNe:
1388-9842, 1879-0844

European Journal of Heart Failure  Wiley-Blackwell

Tipo:
Article
Páginas:
1792-1801
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 13

Citações Recebidas na Scopus: 18

Documentos

  • Não há documentos

Filiações mostrar / ocultar

Keywords

  • Albiglutide; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes; Heart failure

Financiamento

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Comparação de escala de qualidade de vida na insuficiência cardíaca com fração de ejeção reduzida quando realizada no domicílio ou na consulta hospitalar.

Investigador Principal: Francisco Aguiar Vasques Novoa Faria

Estudo Observacional Académico (QualidadeIC) . 2021

Evaluation of thyroid function in patients hospitalized for acute heart failure

Investigador Principal: João Sérgio de Lima Soares Neves

Estudo Clínico Académico (Heart failure) . 2021

Predictors Of The Effectiveness Of Insulin Pumps In Patiens With Type 1 Diabetes Mellitus

Investigador Principal: João Sérgio de Lima Soares Neves

Estudo Clínico Académico . 2021

Impacto da pandemia COVID-19 no controlo metabólico de doentes com Diabetes Mellitus Tipo 1

Investigador Principal: João Sérgio de Lima Soares Neves

Estudo Clínico Académico . 2022

Influence of Diabetes on Response to Ultrasound Guided Hydrodistension Treatment of Adhesive Capsulitis: a Retrospective Study

Investigador Principal: João Sérgio de Lima Soares Neves

Estudo Clínico Académico (Hydrodistension ) . 2022

Influence of Cystic Fibrosis-Related Diabetes on the Severity of Cystic Fibrosis Phenotype

Investigador Principal: João Sérgio de Lima Soares Neves

Estudo Clínico Académico . 2022

Acromegalia: Metabolismo da Glicose Como Possível Preditor de Tumores Mais Agressivos

Investigador Principal: Davide Maurício Costa Carvalho

Estudo Clínico Académico . 2022

Diabetic Neuropathy, Central Nervous System Plasticity and Metabolic Disfunction

Investigador Principal: Davide Maurício Costa Carvalho

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação